PubMed · 1994 · 20 citations · 0 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyMaternal-fetal MedicineWomen's Health PharmacotherapyPregnancyPregnancy PharmacologyReproductive PharmacologyDrug Monitoring During PregnancyPharmacotherapy In PregnancyPregnancy-related PharmacotherapyPregnancy-safe Treatment
BACKGROUND: Kala-azar in pregnant women is difficult to treat because for them the two commonly used drugs, sodium stibogluconate and pentamidine, are not considered safe. We assessed the effect of amphotericin B on pregnancy, on the foetus and kala-azar. METHODS: Five pregnant women were administered amphotericin B at a dose of 1 mg/kg body weight daily starting with 0.5 mg/kg body weight till a total dose of 20 mg/kg body weight was given. The progress of pregnancy was monitored ultrasonographically and the mothers and children were followed for six months. RESULTS: All the 5 women were cured of the disease and there was no harmful effect on the children. CONCLUSION: Amphotericin B cures kala-azar during pregnancy with no harmful effects on the foetus.